| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
|
Ghilardi, G.
|
|
|
33 |
9 |
p. 916-928
|
article
|
| 2 |
Bridging the implementation gap: delivering complex genomic analysis for routine cancer care
|
Beer, P.A.
|
|
|
33 |
9 |
p. 857-859
|
article
|
| 3 |
Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”
|
Dimopoulos, M.A.
|
|
|
33 |
9 |
p. 988
|
article
|
| 4 |
Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?
|
Sasaki, Y.
|
|
|
33 |
9 |
p. 984-985
|
article
|
| 5 |
Editorial Board
|
|
|
|
33 |
9 |
p. iii
|
article
|
| 6 |
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Oaknin, A.
|
|
|
33 |
9 |
p. 860-877
|
article
|
| 7 |
Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation
|
Ciccolini, J.
|
|
|
33 |
9 |
p. 981-982
|
article
|
| 8 |
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
|
Cortiula, F.
|
|
|
33 |
9 |
p. 893-908
|
article
|
| 9 |
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients
|
Bessede, A.
|
|
|
33 |
9 |
p. 909-915
|
article
|
| 10 |
In the phase III IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score
|
Saal, J.
|
|
|
33 |
9 |
p. 982-984
|
article
|
| 11 |
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
|
Maio, M.
|
|
|
33 |
9 |
p. 929-938
|
article
|
| 12 |
Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial
|
Kurokawa, Y.
|
|
|
33 |
9 |
p. 959-967
|
article
|
| 13 |
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study
|
Dimitriou, F.
|
|
|
33 |
9 |
p. 968-980
|
article
|
| 14 |
Table of Contents
|
|
|
|
33 |
9 |
p. i-ii
|
article
|
| 15 |
The deleterious effect of acetaminophen in cancer immunotherapy
|
Berraondo, P.
|
|
|
33 |
9 |
p. 855-856
|
article
|
| 16 |
The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline ☆
|
Di Maio, M.
|
|
|
33 |
9 |
p. 878-892
|
article
|
| 17 |
Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy – an ancillary study of the SAKK 09/10 randomized clinical trial ☆
|
Dal Pra, A.
|
|
|
33 |
9 |
p. 950-958
|
article
|
| 18 |
VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up
|
Loibl, S.
|
|
|
33 |
9 |
p. 986-987
|
article
|
| 19 |
Whole-genome and transcriptome analysis enhances precision cancer treatment options
|
Pleasance, E.
|
|
|
33 |
9 |
p. 939-949
|
article
|
Journal description